Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aroa BiosurgeryASX:ARX +0.88%60 EV-to-EBIT is 32.23 as of Jul. 31, 2026. GuruFocus rates ASX:ARX with a GF Score™ of 60/100 and a GF Value™ of A$0.82 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 467 Medical Devices & Instruments companies, Aroa Biosurgery ranks worse than 74.52% on this metric.
The historical rank and industry rank for Aroa Biosurgery's EV-to-EBIT or its related term are showing as below:
ASX:ARX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -938.67 Med: -31.49 Max: 42.16
Current: 32.23
During the past 7 years, the highest EV-to-EBIT of Aroa Biosurgery was 42.16. The lowest was -938.67. And the median was -31.49.
ASX:ARX's EV-to-EBIT is ranked worse than 74.52% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 18.66
vs ASX:ARX: 32.23
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Aroa Biosurgery's Enterprise Value for the quarter that ended in Mar. 2026 was A$188.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$5.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery EV-to-EBIT Related Terms
Aroa Biosurgery EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's EV-to-EBIT falls into.
Aroa Biosurgery's current Enterprise Value is A$178.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$5.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a EV-to-EBIT of 32.23 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #348 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 74.5%.
Is Aroa Biosurgery's EV-to-EBIT too high?
Aroa Biosurgery's current EV-to-EBIT is 32.23. The Medical Devices & Instruments industry median EV-to-EBIT is 18.66. Aroa Biosurgery's value of 32.23 is 72.7% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #348 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #348 out of 467 companies for EV-to-EBIT. This places Aroa Biosurgery in the lower half of its industry. The industry median EV-to-EBIT is 18.66. Aroa Biosurgery's value of 32.23 is 72.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.66, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current EV-to-EBIT of 32.23 is 72.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current EV-to-EBIT is 32.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.82, compared to a current price of A$0.57 — trading 30.5% below its estimated fair value. The current EV-to-EBIT is 32.23 and 72.7% above the Medical Devices & Instruments industry median of 18.66. Aroa Biosurgery's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current EV-to-EBIT is 32.23 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.57 is trading 30.5% below its estimated GF Value™ of A$0.82.
GuruFocus considers Aroa Biosurgery to be Significantly Undervalued.
Key valuation signals for ASX:ARX:
EV-to-EBIT: 32.23
GF Value™: A$0.82 vs. price of A$0.57 (30.5% below fair value)
Industry Position: 72.7% above the Medical Devices & Instruments median (#348 of 467)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
60GF Score
Get the complete analysis for ASX:ARX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
